Walleye Capital LLC Purchases Shares of 67,007 Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Walleye Capital LLC bought a new stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 67,007 shares of the company's stock, valued at approximately $391,000. Walleye Capital LLC owned approximately 0.12% of Olema Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also made changes to their positions in the company. XTX Topco Ltd raised its stake in shares of Olema Pharmaceuticals by 89.6% in the fourth quarter. XTX Topco Ltd now owns 48,032 shares of the company's stock worth $280,000 after acquiring an additional 22,700 shares during the last quarter. Barclays PLC boosted its position in Olema Pharmaceuticals by 21.0% in the 4th quarter. Barclays PLC now owns 114,879 shares of the company's stock valued at $669,000 after buying an additional 19,964 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of Olema Pharmaceuticals by 435.0% during the fourth quarter. Renaissance Technologies LLC now owns 157,300 shares of the company's stock worth $917,000 after acquiring an additional 127,900 shares during the last quarter. Aristides Capital LLC bought a new position in Olema Pharmaceuticals in the fourth quarter valued at about $189,000. Finally, Wells Fargo & Company MN raised its holdings in Olema Pharmaceuticals by 35.5% during the 4th quarter. Wells Fargo & Company MN now owns 22,725 shares of the company's stock worth $132,000 after purchasing an additional 5,958 shares during the last quarter. 91.78% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

OLMA has been the subject of a number of recent research reports. JPMorgan Chase & Co. dropped their price target on shares of Olema Pharmaceuticals from $30.00 to $28.00 and set an "overweight" rating for the company in a research note on Friday, March 28th. Oppenheimer reiterated an "outperform" rating and set a $25.00 target price (down previously from $30.00) on shares of Olema Pharmaceuticals in a research report on Wednesday, March 19th. Finally, HC Wainwright restated a "buy" rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a research report on Monday.

Olema Pharmaceuticals Stock Down 0.5 %

Olema Pharmaceuticals stock traded down $0.03 during midday trading on Monday, hitting $4.89. 555,384 shares of the stock were exchanged, compared to its average volume of 1,051,141. The stock has a market capitalization of $333.81 million, a PE ratio of -2.23 and a beta of 2.10. The company has a fifty day simple moving average of $4.20 and a two-hundred day simple moving average of $6.78. Olema Pharmaceuticals, Inc. has a 52 week low of $2.86 and a 52 week high of $16.62.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.63) by $0.12. As a group, equities research analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 EPS for the current fiscal year.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.